Clinical trial
Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria
NCT01701583 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria
- Lead sponsor
- University of Colorado, Denver
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2013
- Completion date
- October 31, 2017
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.